Pharmacology of bisphosphonates

Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28.

Abstract

The biological effects of the bisphosphonates (BPs) as inhibitors of calcification and bone resorption were first described in the late 1960s. In the 50 years that have elapsed since then, the BPs have become the leading drugs for the treatment of skeletal disorders characterized by increased bone resorption, including Paget's disease of bone, bone metastases, multiple myeloma, osteoporosis and several childhood inherited disorders. The discovery and development of the BPs as a major class of drugs for the treatment of bone diseases is a paradigm for the successful journey from "bench to bedside and back again". Several of the leading BPs achieved "blockbuster" status as branded drugs. However, these BPs have now come to the end of their patent life, making them highly affordable. The opportunity for new clinical applications for BPs also exists in other areas of medicine such as ageing, cardiovascular disease and radiation protection. Their use as inexpensive generic medicines is therefore likely to continue for many years to come. Fifty years of research into the pharmacology of bisphosphonates have led to a fairly good understanding about how these drugs work and how they can be used safely in patients with metabolic bone diseases. However, while we seemingly know much about these drugs, a number of key aspects related to BP distribution and action remain incompletely understood. This review summarizes the existing knowledge of the (pre)clinical and translational pharmacology of BPs, and highlights areas in which understanding is lacking.

Keywords: Bisphosphonates; bone; osteoporosis; pharmacology.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / pharmacokinetics
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Diseases, Metabolic / diagnosis
  • Bone Diseases, Metabolic / drug therapy*
  • Bone Diseases, Metabolic / epidemiology
  • Bone Diseases, Metabolic / physiopathology
  • Bone Remodeling / drug effects*
  • Diphosphonates / adverse effects
  • Diphosphonates / pharmacokinetics
  • Diphosphonates / therapeutic use*
  • Humans
  • Risk Factors
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Diphosphonates